# Orakl Oncology

> French TechBio company combining patient-derived tumour organoid drug screens with AI to support cancer-trial predictions.

## Why it is interesting

Norrsken VC and Singular co-led a $34M Series A announced November 12, 2026. Orakl's research uses real tumour samples and clinical histories, but its claims about 90% prediction accuracy exceed what has been independently validated in prospective patient trials.

## Profile

- **Latest funding:** Series A (announcement date) — $34M (investor-disclosed; precise legal close day not specified) (November 12, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $34M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-12
- **Latest funding investors:** Norrsken VC, Singular, InfraVia, Serena, Patient Autonome Fund (managed by Bpifrance), teampact.ventures, Plug and Play, Verve Ventures, Speedinvest, HCVC

## Key facts

- November 12, 2026: $34M Series A co-led by Norrsken VC and Singular; $50M company-reported funding since inception.
- Founded in 2023 by Fanny Jaulin, Diane-Laure Pagès and Gustave Ronteix.
- Norrsken says 18 of the world's 20 largest pharmaceutical companies appear in the commercial pipeline; this is not a verified paid-customer count.
- April 2026 SCOPE medRxiv preprint: retrospective trial-arm model assessment, 32 arms from 23 published trials; not peer-reviewed.

## Funding history

- Series A (announcement date) · $34M (investor-disclosed; precise legal close day not specified) · November 12, 2026
  Source: https://www.norrsken.vc/news/orakl-oncology

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 12, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/orakl-oncology